Surinder Kher

Like other search engines (Google or Bing) Radaris collects information from public sources.

Social Networks featuring Surinder Kher

Linkedin

   
surinder kher

Location: Noida Area, India
Industry: Pharmaceuticals
Current: Senior VP at Vanthys Pharmaceutical Development (Lilly-Jubilant JV)
Past: CEO at Clinsys Clinical Research Sr VP and COO at iGATE Clinical Research ( DiagnoSearch Life Sciences) Clinical Research Physician& Manager Medical Business Planning at Eli Lilly & Company India Private Limited manager medical business planning at eli lilly & company india see less... 1 more...
Education: Government Medical College Srinagar, India University of Kashmir CMS Tyndale Biscoe School see less...

Surinder Kher

Location: Noida Area, India
Industry: Research
Current: Chief Executive Officer at Clinsys Clinical Research Ltd

References for Surinder Kher

Web Results

Action steps for designing India's drug regulatory system ...

Dr Surinder Kher. In the recent past, India has seen significant growth in the healthcare sector with international expansion strategies through mergers and acquisitions ...

Cancer research in India: Opportunities and obstacles - Express Pharma

"India is still trying to build up its capabilities in drug discovery and research and development," says Dr Surinder Kher CEO, Jubilent Clinisys and ...

Welcome to FICCI.COM

Dr Surinder Kher Sr. Vice President Clinical and Regulatory Operations Vanthys-The Eli Lilly-Bubilant Drug Development JV Co.

domain-b.com : domain - B : Indian business : News Review : 21 ...

Mumbai: Surinder Kher, former vice-president (operations) of Neeman Medical India, a site management organisation for drugmakers ...

MAGINDIA - Contract research is the buzz in healthcare

It is a logical and synergistic extension for healthcare companies,” said Surinder Kher, chief executive officer, Jubilant Clinsys. With access to patients, doctors and ...

Contract research is the buzz in healthcare

It is a logical and synergistic extension for healthcare companies,” said Surinder Kher, chief executive officer, Jubilant Clinsys. With access to patients, doctors and ...

BioSpectrumIndia - the business of biotech - Indian CROs have an ...

Dr Surinder Kher, CEO, Jubilant Clinsys, New Delhi, said, "Certainly this is a positive step. This notification will translate into the Indian companies offering a 12.36 percent ...

KECSS

Surinder Kher : C-7, Pamposh Enclave, New Delhi-110048 Tel. 91-11-643-3740(R) Member: 12. Smt. Jaikishori Pandit,

BioSpectrumIndia - the business of biotech - Leveraging the India-edge

—Dr Surinder Kher, Senior VP, Vanthys Pharmaceutical Development Key achievements in 2009. Jubilant entered into a joint venture with US-based Eli Lilly to focus on drug development

India becoming preferred clinical research destination ...

If we take the US as a benchmark then clinical trials in India can cost anywhere between 25 per cent to 50 per cent less, said Surinder Kher, senior vice-president ...

"Affordability through Innovation in Drug Discovery, Clinical ...

... Trends in Clinical Trial Design and Execution : bridging gaps in HR, Regulatory capacity and Infrastructure • Need for science based regulations Panelists • Dr.Surinder Kher ...